Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CASR | P41180 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1854219 | 1.00 | MEN1 (0.44) | MEN1GAAKMT2ATDP1CA12 | |
| SCHEMBL584353 | 1.00 | MEN1 (0.44) | MEN1GAAKMT2ATDP1CA12 | |
| Hydrochloric Acid SCHEMBL584352 | 0.98 | MEN1 (0.42) | MEN1GAAKMT2ATDP1CA12 | |
| Hydrochloric Acid SCHEMBL2681080 | 0.98 | MEN1 (0.42) | MEN1GAAKMT2ATDP1CA12 | |
| Hydrochloric Acid SCHEMBL584354 | 0.98 | MEN1 (0.42) | MEN1GAAKMT2ATDP1CA12 | |
| Hydrochloric Acid SCHEMBL23575089 | 0.98 | MEN1 (0.42) | MEN1GAAKMT2ATDP1CA12 | |
| SCHEMBL27711551 | 0.91 | MEN1 (0.45) | MEN1GAAKMT2ATDP1CA12 | |
| Hydrochloric Acid SCHEMBL3894157 | 0.89 | MEN1 (0.44) | MEN1GAAKMT2ATDP1CA12 | |
| SCHEMBL20999543 | 0.89 | MAOA (0.39) | MEN1GAAKMT2ATDP1CA12 | |
| SCHEMBL23455567 | 0.89 | MAOA (0.39) | MEN1GAAKMT2ATDP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307534-A | LTA4H inhibitors and uses thereof | 上海海雁医药科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20230226207-A1 | Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof | SYSTIMMUNE, INC. | 2023-07-20 | — | — | US | disclosed |
| CN-115942872-A | Method for inducing environmental stress tolerance in plants | 味之素株式会社 | 2023-04-07 | — | — | CN | disclosed |
| CN-115916784-A | Novel imidazopyrazine derivatives | 豪夫迈·罗氏有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-114380887-A | Liquid phase fragment synthesis method of snake venom-like tripeptide | 深圳翰宇药业股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| WO-2021136808-A1 | CONJUGATES UNDERGOING INTRAMOLECULAR REARRANGEMENTS | ASCENDIS PHARMA A/S (DK) | 2021-07-08 | — | — | WO | disclosed |
| US-9676785-B2 | HCV protease inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-06-13 | — | — | US | disclosed |
| US-9676785-B2 | HCV protease inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-06-13 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-6274620-B1 | 2-BENZENESULFONYLAMINO-3-((5-BROMO-THIOPHENE-2-CARBONYL)-AMINO )PROPIONIC ACID-TERT-BUTYL ESTERS AS ANGIOGENESIS INHIBITORS; ANTICARCINOGENIC AGENTS; OSTEOPOROSIS, RESTENOSIS, AND OCULAR NEOVASCULARIZATION | BIOCHEM PHARMA INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| EP-1115724-A1 | QUINOLIZINONES AS INTEGRIN INHIBITORS | Shire Biochem Inc. (CA) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000075129-A1 | THIOPHENE INTEGRIN INHIBITORS | SHIRE BIOCHEM INC. (CA) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000017197-A1 | QUINOLIZINONES AS INTEGRIN INHIBITORS | BIOCHEM PHARMA INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| US-5972984-A | LOW MOLECULAR WEIGHT PEPTIDYL COMPOUNDS THAT DO NOT HAVE A THIOL MOIETY. | MERCK & CO., INC. (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0833633-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5760028-A | TREATING CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, MACULAR DEGENERATION | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-06-02 | — | — | US | disclosed |
| US-5756528-A | ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0833633-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996039137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226207-A1 | Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof | SLC7A1, CD44, DCLRE1A | MEN1 753/4885GAA 3473/4885KMT2A 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.